The company behind Wegovy: who makes it and what that means for you

Is Novo Nordisk the same company that makes Ozempic?

Yes. Novo Nordisk manufactures both Wegovy and Ozempic, and both contain semaglutide. The difference is the licence, not the molecule. Ozempic is licensed for type 2 diabetes management; Wegovy is licensed specifically for weight management, at a higher maintenance dose. This distinction matters in practice: a pharmacist cannot legally dispense Ozempic for weight loss in the UK, even though it contains the same active ingredient. The MHRA licenses each medicine for a defined indication, and that licence shapes what a prescriber can legally prescribe it for.

A question our prescribers hear most weeks is whether someone can switch from Ozempic to Wegovy or vice versa. The short answer is that any switch is a clinical decision, not an administrative one. If you are curious about how the semaglutide molecule itself works and where it originates, our page on semaglutide's origins covers the science behind the GLP-1 pathway in plain language.

Novo Nordisk has deep roots in diabetes care — insulin was central to its business for most of the twentieth century. Its pivot into obesity medicine represents a deliberate strategic shift, and semaglutide is now one of the most studied weight-loss compounds in clinical history. The STEP 1 trial, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose.

How has the company expanded Wegovy's licensed uses in the UK?

Novo Nordisk has pursued a series of additional UK approvals beyond the original weight-management indication. In January 2026, the MHRA approved a 7.2mg maintenance dose for adults with obesity, and by April 2026 a dedicated single-dose 7.2mg pen received approval — designed for weekly self-injection with a built-in covered needle and auto-lock mechanism. Trials at this dose reported average weight loss of around 20.7% over 72 weeks, approaching results seen with the highest doses of tirzepatide.

Then, on 11 June 2026, the MHRA approved Wegovy tablets as the UK's first oral GLP-1 medicine licensed for weight management. The tablet uses an absorption enhancer called SNAC to allow semaglutide to cross the stomach lining. It requires no refrigeration, which makes it more convenient for many patients. You can read the full background on our Wegovy overview page, which covers both the injection and tablet formulations.

Novo Nordisk also received conditional UK approval in July 2026 for semaglutide in MASH (a form of progressive fatty liver disease) marking another step beyond weight management. For people researching Wegovy specifically for weight loss, these additional approvals are context rather than direct relevance, but they reflect the breadth of clinical evidence the company has built around this compound.

What does Novo Nordisk's position as the manufacturer mean for supply and safety?

Manufacturing by a globally regulated pharmaceutical company means Wegovy supplied through licensed UK channels meets MHRA standards for purity, potency, and consistency. This is not a minor point. The MHRA has warned publicly and repeatedly about counterfeit weight-loss pens sold online, some of which have contained insulin rather than semaglutide, a potentially life-threatening substitution. Buying through an unverified source, without a valid prescription issued after proper clinical assessment, removes every one of those manufacturing safeguards.

When you use a GPhC-registered pharmacy in the UK, you can verify its registration at the GPhC online register before handing over any personal or payment details. Medicines supplied through that regulated route come from Novo Nordisk's authorised UK supply chain. Questions about the cost of treatment in that context are worth reading alongside the manufacturing story: our page on Wegovy pricing in the UK explains what legitimate private treatment typically includes.

Details about how Novo Nordisk brings Wegovy to UK patients specifically, including its authorised supplier relationships, are covered on our page on Wegovy's pharmaceutical company background. The drug-company context for Wegovy also addresses how the branded medicine sits within Novo Nordisk's wider portfolio.

Who decides whether Wegovy is right for a specific patient?

Novo Nordisk develops and supplies the medicine. The decision about whether it is clinically appropriate for any individual person rests entirely with a prescriber, not with the manufacturer. In the UK, that means a GPhC-registered Independent Prescriber reviews your consultation, your medical history, your current medications, and your BMI before any prescription is issued. The manufacturer's approved licence sets the eligibility framework (BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea) but the prescriber interprets that framework in light of your specific circumstances.

For a broader look at what semaglutide is and how it works, or to read about the company structure behind Wegovy's development, those pages go into more clinical and corporate detail. If you are weighing up treatment options more generally, our weight-loss treatment overview sets out what is currently licensed in the UK and how private and NHS routes compare.

If you have specific questions for a prescriber, starting a free consultation is the most direct route to a clinically grounded answer. Our prescribers review consultations the same day, and they read every response personally.